These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 10509549)

  • 21. Effects of fenoldopam, a specific dopamine receptor agonist, on blood pressure and left ventricular function in systemic hypertension.
    Caruana MP; Heber M; Brigden G; Raftery EB
    Br J Clin Pharmacol; 1987 Dec; 24(6):721-7. PubMed ID: 2894216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etamicastat, a novel dopamine β-hydroxylase inhibitor: tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension.
    Almeida L; Nunes T; Costa R; Rocha JF; Vaz-da-Silva M; Soares-da-Silva P
    Clin Ther; 2013 Dec; 35(12):1983-96. PubMed ID: 24296323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and tolerability of nisoldipine coat-core formulation in the treatment of essential hypertension: The South African Multicenter ANCHOR Study. Ambulatory Nisoldipine Coat-Core Hypertension Outpatient Response (ANCHOR) Investigators.
    Opie LH; Müller FO; Myburgh DP; Rosendorff C; Sareli P; Seedat YK; Weich DJ; Luus HG
    Am J Hypertens; 1997 Mar; 10(3):250-60. PubMed ID: 9056681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of dopamine and fenoldopam effects on renal blood flow and prostacyclin excretion in normal and essential hypertensive subjects.
    Bughi S; Horton R; Antonipillai I; Manoogian C; Ehrlich L; Nadler J
    J Clin Endocrinol Metab; 1989 Dec; 69(6):1116-21. PubMed ID: 2573613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function.
    Shusterman NH; Elliott WJ; White WB
    Am J Med; 1993 Aug; 95(2):161-8. PubMed ID: 8102835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hemodynamic and humoral effects at rest and after head-up tilt tests during 24-hour infusion of a new nitrate ester, ITF 296, compared with ISDN and placebo in healthy volunteers: a double-blind, randomized, within-subject study.
    Sardina M; Warrington SJ; Boyce M; Johnston A; Bianchini C
    J Cardiovasc Pharmacol; 1995; 26 Suppl 4():S80-90. PubMed ID: 8839231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of fenoldopam on coronary conduit blood flow after coronary artery bypass graft surgery.
    Halpenny M; Lakshmi S; O'Donnell A; O'Callaghan-Enright S; O'Connell D; Shorten G
    J Cardiothorac Vasc Anesth; 2001 Feb; 15(1):72-6. PubMed ID: 11254844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clevidipine: a review of its use in the management of acute hypertension.
    Deeks ED; Keating GM; Keam SJ
    Am J Cardiovasc Drugs; 2009; 9(2):117-34. PubMed ID: 19331440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence against a role for dopamine D1 receptors in the myocardium of the pig.
    Van Woerkens LJ; Duncker DJ; Den Boer MO; McFalls EO; Sassen LM; Saxena PR; Verdouw PD
    Br J Pharmacol; 1991 Sep; 104(1):246-50. PubMed ID: 1686206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of atrial natriuretic peptide (8-33-Met ANP) in patients with hypertension.
    Franco-Saenz R; Somani P; Mulrow PJ
    Am J Hypertens; 1992 May; 5(5 Pt 1):266-75. PubMed ID: 1533767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential effects between intravenous and targeted renal delivery of fenoldopam on renal function and blood pressure in patients undergoing cardiac catheterization.
    Teirstein PS; Price MJ; Mathur VS; Madyoon H; Sawhney N; Baim DS
    Am J Cardiol; 2006 Apr; 97(7):1076-81. PubMed ID: 16563920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopamine1 agonist fenoldopam.
    Murphy MB; McCoy CE; Weber RR; Frederickson ED; Douglas FL; Goldberg LI
    Circulation; 1987 Dec; 76(6):1312-8. PubMed ID: 2890447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
    White WB; Lacourciere Y; Davidai G
    Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular and renal profile of acute peripheral dopamine1-receptor agonism with fenoldopam.
    Glück Z; Jossen L; Weidmann P; Gnädinger MP; Peheim E
    Hypertension; 1987 Jul; 10(1):43-54. PubMed ID: 2885268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of amlodipine and long-acting diltiazem in the treatment of mild or moderate hypertension.
    Horwitz LD; Weinberger HD; Clegg L
    Am J Hypertens; 1997 Nov; 10(11):1263-9. PubMed ID: 9397246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effects of fenoldopam mesylate and nitroprusside on left ventricular performance in severe systemic hypertension.
    Hackman BB; Griffin B; Mills M; Ramanathan KB
    Am J Cardiol; 1992 Apr; 69(9):918-22. PubMed ID: 1347965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hemodynamic and sympathetic effects of fenoldopam and sodium nitroprusside.
    Yakazu Y; Iwasawa K; Narita H; Kindscher JD; Benson KT; Goto H
    Acta Anaesthesiol Scand; 2001 Oct; 45(9):1176-80. PubMed ID: 11683671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension.
    Murphy MB; Murray C; Shorten GD
    N Engl J Med; 2001 Nov; 345(21):1548-57. PubMed ID: 11794223
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy and safety of fosinopril/hydrochlorothiazide combinations on ambulatory blood pressure profiles in hypertension. Fosinopril/Hydrochlorothiazide Investigators.
    Guthrie R; Reggi DR; Plesher MM; Saini RK; Battikha JP
    Am J Hypertens; 1996 Apr; 9(4 Pt 1):306-11. PubMed ID: 8722432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension.
    Sweet CS; Bradstreet DC; Berman RS; Jallard N; Saenz A; Weidler DJ
    Am J Hypertens; 1994 Dec; 7(12):1035-40. PubMed ID: 7702795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.